GFOR vs. AIM, SQZ, SRNE, GNCAQ, GNCA, ELOX, PRME, IKT, PLX, and IZTC
Should you be buying Graf Acquisition Corp IV stock or one of its competitors? The main competitors of Graf Acquisition Corp IV include AIM ImmunoTech (AIM), SQZ Biotechnologies (SQZ), Sorrento Therapeutics (SRNE), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), and Invizyne Technologies (IZTC). These companies are all part of the "biological products, except diagnostic" industry.
Graf Acquisition Corp IV vs. Its Competitors
Graf Acquisition Corp IV (NYSE:GFOR) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Graf Acquisition Corp IV has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Graf Acquisition Corp IV's return on equity of -2.50% beat AIM ImmunoTech's return on equity.
AIM ImmunoTech has a consensus target price of $275.00, indicating a potential upside of 9,617.31%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than Graf Acquisition Corp IV.
28.5% of Graf Acquisition Corp IV shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 20.0% of Graf Acquisition Corp IV shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Graf Acquisition Corp IV has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
In the previous week, AIM ImmunoTech had 10 more articles in the media than Graf Acquisition Corp IV. MarketBeat recorded 10 mentions for AIM ImmunoTech and 0 mentions for Graf Acquisition Corp IV. AIM ImmunoTech's average media sentiment score of 0.41 beat Graf Acquisition Corp IV's score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the news media.
Graf Acquisition Corp IV has higher earnings, but lower revenue than AIM ImmunoTech.
Summary
AIM ImmunoTech beats Graf Acquisition Corp IV on 7 of the 13 factors compared between the two stocks.
Get Graf Acquisition Corp IV News Delivered to You Automatically
Sign up to receive the latest news and ratings for GFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graf Acquisition Corp IV Competitors List
Related Companies and Tools
This page (NYSE:GFOR) was last updated on 8/3/2025 by MarketBeat.com Staff
Free GFOR Stock Alerts